Drugs / MB-001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06363383 | May 2024 → Jul 2025 | ulcerative colitis | Mage Biologics | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07374471 | Apr 2026 → Jul 2028 expected | ulcerative colitis | Mage Biologics | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-06-18 | Tillotts Pharma AG | Mage Biologics announces first subject dosed in a Phase 1 trial with MB-001, an orally administered antibody for Inflammatory Bowel Disease tillotts.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MB-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07374471 ↗ |
| Modality | Protein / enzyme biologic | “oral biologic” NCT07374471 ↗ |
| Route | Oral | “Oral, delayed release formulation of a biologic drug” NCT06363383 ↗ |